Thomas Haag, Ph.D.


Seyfarth Shaw LLP

Thomas Haag is a partner in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington D.C. office where he co-chairs the firm’s Chemical & Life Sciences Patent Team. His practice focuses on pharmaceutical and biotechnology patent litigation, due diligence, prosecution and licensing/transactional matters; and in particular Hatch-Waxman litigation and Biosimilars related matters.

He has extensive experience creating and strategically managing large patent portfolios, as well as drafting and negotiating biomedical patent licenses, asset purchase agreements and joint-development agreements. His technical expertise is in molecular biology related technologies including those in the fields of immuno-oncology, cancer/infectious disease vaccines, nucleic acid-based therapeutics, stem-cell therapeutics, gene editing and therapy, epigenetics, transgenic plants, next generation sequencing (NGS), biologics and biosimilars.

Dr. Haag has firsthand experience in translating biotechnologies into successful commercial ventures.  While at his previous firm, Fanelli Haag, he served as acting CEO of PhosImmune, Inc., an immuno-oncology neoantigen discovery startup company co-founded and built by Fanelli Haag and ultimately acquired by Agenus, Inc. (NASDAQ: AGEN) in December 2015. 

Dr. Haag graduated from The George Washington University Law School with honors, where he also received the ABA/BNA Award for Excellence in the Study of Intellectual Property Law. Dr. Haag received a B.S. in Biology and Ph.D. in Molecular, Cell & Developmental Biology from UCLA where he was an NIH Pre-Doctoral Fellow in Genetic Mechanisms.